Yourgene Health Plc (LON:YGEN – Free Report)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as GBX 0.19 ($0.00) and last traded at GBX 0.20 ($0.00), with a volume of 23817568 shares changing hands. The stock had previously closed at GBX 0.23 ($0.00). Yourgene Health Trading […]
Yourgene Health Plc (LON:YGEN – Get Rating) insider Hayden Jeffreys purchased 355,450 shares of the firm’s stock in a transaction dated Monday, March 21st. The stock was acquired at an average cost of GBX 8 ($0.11) per share, for a total transaction of £28,436 ($37,435.49). YGEN opened at GBX 8.58 ($0.11) on Wednesday. The stock’s […]
19 May 2021 | 07:41am
StockMarketWire.com - Diagnostics company Yourgene Health said it had launched a distribution partnership with Dubai-headquartered Alliance Global across territories in the Middle East and Africa.
Yourgene said the pact would expand its geographical footprint and customer base. Alliance Global is the largest biomedical gateway in the Middle East, Africa, and Asia and is both a well-respected and a long-term partner for many international and US diagnostics groups looking to pursue a strategy of expansion in these regions, Yourgene added.
It would be focusing on Yourgene s product portfolio of non-invasive prenatal testing, reproductive health range, DPYD genotyping and new size selection and enrichment technologies.
1 March 2021 | 09:08am
StockMarketWire.com - Molecular diagnostics group Yourgene Health said its secured a $1.5 million supply agreement with a large US clinical laboratory group.
The agreement, spanning five years, granted the partner non-exclusive access to Yourgene s Ranger technology, gained as part of the acquisition of Coastal Genomics in August 2020.
At 9:08am: [LON:YGEN] share price was 0p at 16.75p
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Latest share price and company details:
8 February 2021 | 07:12am
StockMarketWire.com - Molecular diagnostics group Yourgene Health warned that it would fall short of its previous revenue forecasts, citing the Covid-19 pandemic s impact on ordering patterns.
Revenue for the year through March was now expected in the range of £18 million-to-£20 million, lower than previous guidance but still representing year-on-year growth of around 10-20%.
Yourgene Health said sales growth had been driven by its European-focused product lines in testing for cystic fibrosis, prenatal aneuploidies and DPD.
However, that had been offset by a significant pandemic-related impact on international markets for non-invasive prenatal testing outside Europe.
Travel restrictions had also hurt the company s ability to convert new accounts, grow new product sales and commence new initiatives.